In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy

Paul A. Foster, Simon P. Newman, Surindaer. K. Chander, Chloe Stengel, Roma Jhalli, Lawrence L. W. Woo, Barry V. L. Potter, Michael J. Reed, Atul Purohit

Research output: Contribution to journalArticle

52 Citations (Scopus)
Original languageEnglish
Pages (from-to)5543-5549
JournalClinical Cancer Research
Volume12
Issue number18
DOIs
Publication statusPublished - 2006

Cite this

Foster, P. A., Newman, S. P., Chander, S. K., Stengel, C., Jhalli, R., Woo, L. L. W., Potter, B. V. L., Reed, M. J., & Purohit, A. (2006). In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy. Clinical Cancer Research, 12(18), 5543-5549. https://doi.org/10.1158/1078-0432.CCR-06-0632